Meta-Analysis of Gastrointestinal Adverse Events from Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia

Meta-Analysis of Gastrointestinal Adverse Events from Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia

Tyrosine kinase inhibitors (TKIs) are the frontline therapy for BCR-ABL (Ph+) chronic myeloid leukemia (CML). A systematic meta-analysis of 43 peer-reviewed studies with 10,769 CML patients compared the incidence of gastrointestinal adverse events (GI AEs) in a large heterogeneous CML population as...

Full description

Bibliographic Details
Main Authors: Prahathishree Mohanavelu, Mira Mutnick, Nidhi Mehra, Brandon White, Sparsh Kudrimoti, Kaci Hernandez Kluesner, Xinyu Chen, Tim Nguyen, Elaina Horlander, Helena Thenot, Vamsi Kota, Cassie S. Mitchell
Format: Article
Language:English
Published: MDPI AG 2021-04-01
Series:Cancers
Subjects:
chronic myeloid leukemia
tyrosine kinase inhibitor
gastrointestinal adverse event
quality of life
Online Access:https://www.mdpi.com/2072-6694/13/7/1643

Internet

https://www.mdpi.com/2072-6694/13/7/1643

Similar Items